NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD
Post# of 85
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in autism spectrum disorder (“ASD”) therapeutics, and its commitment to addressing unmet needs within the ASD community. “PaxMedica is pleased to share our vision and progress with the wider community,” said Howard Weisman, chairman and CEO of PaxMedica. “We believe that our work has the potential to transform the treatment landscape for ASD, offering a new horizon of hope and support for affected individuals and their loved ones.”
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer